Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 8 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

anumed international llc - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 6 [hp_c] in 200 ml - improve sleep, increase energy, anti-aging benefits, increase lean muscle reduce fat, increase lean mass, improve sleep, increase energy, reduce nervousness, decrease stress and anxiety, improve sense of well-being

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate -

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8.8mg ((includes 0.8 mg overfill)) - injection with diluent - 8 mg - active: somatropin 8.8mg ((includes 0.8 mg overfill)) excipient: phosphoric acid sodium hydroxide sucrose metacresol water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Израел - Енглески - Ministry of Health

novo nordisk ltd., israel - somatropin - solution for injection - somatropin 3.3 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency. תוספת התוויה: 5/6/2019indication:children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome.short stature in children with renal insufficiency.growth disturbance (current height sds < -2.5 and parental adjusted height sds < -1) in short childre

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - somatropin -